✦ LIBER ✦

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

✍ Scribed by Suzuki, Yoshiyuki; Ikeda, Kenji; Suzuki, Fumitaka; Toyota, Joji; Karino, Yoshiyasu; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hu, Wenhua; Eley, Timothy; McPhee, Fiona; Hughes, Eric; Kumada, Hiromitsu

Book ID: 121528853
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 941 KB
Volume: 58
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2012.09.037

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O166 ALL-ORAL DUAL THERAPY WITH DACLATAS

O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS

✍ Manns, M.; Pol, S.; Jacobson, I.; Marcellin, P.; Gordon, S.; Peng, C.-Y.; Chang, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 120 KB

763 All-Oral Therapy With Daclatasvir in

763 All-Oral Therapy With Daclatasvir in Combination With Asunaprevir and Bms-791325 for Treatment-Naive Patients With Chronic HCV Genotype 4 Infection

✍ Hassanein, Tarek; Everson, Gregory T.; Sims, Karen; Bennett, Michael T.; Gitlin, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 166 KB

P1163 ALL-ORAL THERAPY WITH DACLATASVIR

P1163 ALL-ORAL THERAPY WITH DACLATASVIR IN COMBINATION WITH ASUNAPREVIR AND BMS-791325 FOR TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE 4 INFECTION

✍ Hassanein, T.; Sims, K.; Bennett, M.; Gitlin, N.; Lawitz, E.; Nguyen, T.; Webste 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Efficacy of an Interferon- and Ribavirin

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection

✍ Everson, Gregory T.; Sims, Karen D.; Rodriguez-Torres, Maribel; Hézode, Christop 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 608 KB

P1300 EFFICACY AND SAFETY OF DACLATASVIR

P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDY

✍ Kao, J.-H.; Heo, J.; Yoffe, B.; Sievert, W.; Jacobson, I.; Bessone, F.; Peng, C. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 129 KB

14 DUAL ORAL THERAPY WITH THE NS5A INHIB

14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN

✍ F. Suzuki; K. Ikeda; J. Toyota; Y. Karino; T. Ohmura; K. Chayama; S. Takahashi; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 117 KB